Oruka Therapeutics, INC

Oruka Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 2, 2026, including the election of directors and ratification of its independent auditor.

Oruka Therapeutics announced positive Week 16 results from its Phase 2a EVERLAST-A trial for ORKA-001 in moderate-to-severe psoriasis, showing significant skin clearance and a favorable safety profile.

Oruka Therapeutics, Inc. announced the appointment of Christopher Martin, a seasoned pharmaceutical commercial leader, to its Board of Directors, following the resignation of Cameron Turtle.

Oruka Therapeutics announced a $180 million private placement and positive interim Phase 1 results for its lead asset, ORKA-001, targeting chronic skin diseases.

Oruka Therapeutics, Inc. has appointed Laura Sandler, formerly Senior Vice President of Operations, as its new Chief Operating Officer, effective July 1, 2025, with a compensation package including a $460,000 base salary and significant equity grants.

Oruka Therapeutics, Inc. announced the successful passage of all proposals at its Annual Meeting of Stockholders on June 2, 2025, including the re-election of two Class I directors and the ratification of its independent auditor.

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $30.3 million for Q3 2025, while advancing its lead programs ORKA-001 and ORKA-002 and securing $169.6 million in new financing.

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported increased losses in Q2 2025 as it advances its lead psoriasis programs, ORKA-001 and ORKA-002, into clinical trials.

Oruka Therapeutics reports a net loss of $21.0 million for the first quarter of 2025, focusing on the development of novel monoclonal antibody therapeutics.

Oruka Therapeutics reports its financial results for the quarter ended September 30, 2024, highlighting a significant PIPE financing and progress in its clinical development programs.

ARCA Biopharma has entered into a merger agreement with Oruka Therapeutics, planning to dispose of its legacy assets and issue a special dividend to existing shareholders.

ARCA Biopharma has entered into a merger agreement with Oruka Therapeutics, while also reporting a net loss of $2.009 million for the first quarter of 2024.

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $105.4 million for 2025, while advancing its lead programs ORKA-001 and ORKA-002 in psoriasis and other inflammatory indications.

Oruka Therapeutics' 2024 10-K filing outlines its focus on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory and immunology conditions, with key programs ORKA-001 and ORKA-002 progressing towards clinical trials.

ARCA Biopharma's 10-K filing details its strategic review process, Gencaro's development for atrial fibrillation, and financial position through mid-2025.

Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on July 15, 2026.

Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 9,999 shares of common stock on July 13, 2026.

Fairmount Funds Management LLC, along with affiliated entities, has converted a significant portion of Series B Preferred Stock into common stock of Oruka Therapeutics, Inc.

Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock.

Senior Vice President of Finance Arjun Agarwal exercised stock options and sold shares of Oruka Therapeutics under a 10b5-1 plan.

Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a 10b5-1 plan.

Oruka Therapeutics schedules its 2026 Annual Meeting of Stockholders for June 2, 2026, to address director elections, auditor ratification, and executive compensation.

Oruka Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 2, 2025, with key voting items including the election of directors, ratification of the accounting firm, and executive compensation.

Oruka Therapeutics will hold its annual stockholders meeting virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of future compensation votes.

Oruka Therapeutics is holding a special meeting on November 14, 2024, to seek stockholder approval for the conversion of its Series A Non-Voting Convertible Preferred Stock into common stock, as required by Nasdaq listing rules.

Oruka Therapeutics has filed a registration statement for the resale of up to 8.7 million shares of its common stock by selling stockholders, following a recent private placement.

Fairmount Funds Management LLC and its affiliates have filed an amendment to their Schedule 13D, reporting changes in their beneficial ownership of Oruka Therapeutics, Inc. common stock.

Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Oruka Therapeutics following a lock-up agreement.

Fairmount Funds Management LLC and affiliates increased their beneficial ownership in ORUKA THERAPEUTICS, INC. to 19.99% through a $5 million private placement.

Fairmount Funds Management LLC and its affiliates have filed an Amendment No. 3 to their Schedule 13D for ORUKA THERAPEUTICS, INC., updating their reported beneficial ownership percentage due to a change in the issuer's total outstanding common stock, while their actual shareholdings remain unchanged.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Oruka Therapeutics Inc. following an internal realignment.

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 4.3% in Oruka Therapeutics, Inc., as per their Schedule 13G/A filing.

Deep Track Capital and affiliated entities disclose an updated beneficial ownership of Oruka Therapeutics, Inc. common stock, collectively holding approximately 8.93%.

The Vanguard Group has reported a 5.06% beneficial ownership stake in Oruka Therapeutics Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 6.6% beneficial ownership stake in Oruka Therapeutics, Inc., holding 3,175,483 shares of common stock as of December 31, 2025.